EGFR and head and neck squamous cell carcinoma: It has been suggested that EGFR-directed therapies can be improved by the concurrent targeting of EGFR-related PI3K/Akt signaling and by searching for combination therapies with other molecular targets important for the growth of HNSCC [4,5].